Xella Health has secured an initial investment of more than $3.7 million in pre-seed financing to develop a specialized healthcare platform focused on women's health. The planned innovation will utilize multi-omic diagnostics and telemedicine.
Xella Health's platform intends to analyze biological data from various sources — including menstrual fluid and blood — to provide insights and predictive analytics concerning fertility, hormonal conditions, cancer risk, and overall aging. These insights are supported by access to clinical professionals and artificial intelligence.
Overall, the company aims to deliver "a new category of women’s health — one that moves beyond symptom-based care and fragmented testing to deliver integrated biological insight, clarity, and foresight." Xella Health reports significant pre-launch interest with more than 10,000 women joining the waitlist for this innovation ahead of the planned Spring 2026 launch.